Searched for: in-biosketch:true
person:katzs04
"Mind the Gap": an unmet need for new therapy in IBD
Katz, Seymour
Most physicians believe that the drugs they prescribe will work in their patients and thus have made little preparation for alternative strategies in the event of failure. In the treatment of inflammatory bowel disease (IBD), achieving a remission rate of 20% to 30% or a response rate of 50% to 60% is highly acceptable. This review focuses primarily on placebo-controlled trials that evaluated 'usual' treatments for IBD in terms of induction and maintenance of remission, and identifies the 'gaps' (ie, the percentage of patients lacking any benefit) in currently available treatments for IBD. Approximately, 40% to 60% of patients will not benefit from the available treatments, indicating a considerable unmet need for new, more effective therapies
PMID: 17881924
ISSN: 0192-0790
CID: 75412
Cheilitis granomatosa: Crohn's disease of the lip? [Letter]
Wiesen, Ari; David, Oustecky; Katz, Seymour
PMID: 17881936
ISSN: 0192-0790
CID: 114397
Gastroduodenal Crohn's disease (GDCD): A case of dramatic response to selective granulocyte-monocyte apheresis (GMA) [Meeting Abstract]
Sood, S; Savetsky, IL; Erber, JA; Erber, WF; Katz, S
ISI:000249397800435
ISSN: 0002-9270
CID: 74155
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
Sands, Bruce E; Kozarek, Richard; Spainhour, Jack; Barish, Charles F; Becker, Scott; Goldberg, Lawrence; Katz, Seymour; Goldblum, Ronald; Harrigan, Rena; Hilton, Deborah; Hanauer, Stephen B
BACKGROUND: Natalizumab, a humanized monoclonal IgG(4) antibody to alpha4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied. METHODS: Seventy-nine adult patients with active CD (Crohn's Disease Activity Index [CDAI] score > or = 150) despite ongoing infliximab treatment were randomized 2:1 to receive 3 intravenous infusions of natalizumab (300 mg; n = 52) or placebo (n = 27) every 4 weeks. Patients received infliximab (5 mg/kg) every 8 weeks for at least 10 weeks before randomization and throughout the study. The primary objective was to assess the short-term safety and tolerability of natalizumab in patients concurrently receiving infliximab. Secondary and tertiary objectives included measures of efficacy, health-related quality of life (HRQoL), and effects on inflammatory markers. A subset of patients also participated in a pharmacokinetic/pharmacodynamic (PK/PD) analysis of the effects of concurrent treatment. RESULTS: Incidence of adverse events (AEs) was similar in the treatment groups. AEs frequently reported in both groups were headache, CD exacerbation, nausea, and nasopharyngitis. No patient had a hypersensitivity-like reaction to natalizumab, whereas 4 patients (5%) experienced reactions to infliximab. Two patients (4%) developed anti-natalizumab antibodies; 10 patients (14%) developed anti-infliximab antibodies. The mean CDAI score decreased with natalizumab plus infliximab but was unchanged with infliximab alone (-37.7 versus +3.5; P = 0.084). Patients in both groups showed small increases in HRQoL (P = 0.811). No drug-drug interactions were noted. CONCLUSIONS: The combination of natalizumab plus infliximab was well tolerated. Several positive trends suggested that treating patients not in remission with infliximab plus natalizumab had greater efficacy than treatment with infliximab alone
PMID: 17206633
ISSN: 1078-0998
CID: 114399
Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease
Katz, Seymour
Leukocytapheresis has reemerged as a novel "nondrug" approach in the treatment of inflammatory bowel disease. The technique involves the extracorporeal passage of peripheral blood through a column of cellulose diacetate beads (Adacolumn) or a nonwoven polyester fiber filter (Cellsorba). The benefits accrued from the filtered extraction of granulocytes, monocytes (Adacolumn), and lymphocytes (Cellsorba) appear greater than the simple extraction of these cells. There appears to be an immunologic modulation of leukocytes and dendritic cells and a diminished response to proinflammatory cytokines. Unfortunately, blinded placebo-controlled trials are lacking. Nevertheless, the aggregate clinical experience detailed in this review suggests a relatively safe and attractive alternative to current inflammatory bowel disease therapies. Randomized, controlled sham trials are in progress.
PMCID:5359938
PMID: 28331481
ISSN: 1554-7914
CID: 2494852
Safety and colon-cleansing efficacy of a new residue-free formulation of sodium phosphate tablets
Rex, Douglas K; Schwartz, Howard; Goldstein, Michael; Popp, John; Katz, Seymour; Barish, Charles; Karlstadt, Robyn G; Rose, Martin; Walker, Kelli; Lottes, Sandra; Ettinger, Nancy; Zhang, Bing
OBJECTIVE: A residue-free sodium phosphate tablet (RF-NaP) was formulated that lacks microcrystalline cellulose, which can appear as a whitish residue in the colon. A multicenter, randomized, investigator-blinded study was conducted to compare the colon-cleansing efficacy of 40 or 32 tablets of RF-NaP with the marketed 40-tablet NaP treatment regimen. METHODS: Eight hundred sixteen patients were randomized prior to colonoscopy to receive either 40 tablets (60 g) of NaP or RF-NaP or 32 tablets (48 g) of RF-NaP. Colon cleansing was assessed using a 4-point scale based on retained 'colonic contents.' The primary end point was overall colon-cleansing response rate to treatment (score of excellent/good) versus nonresponse (fair/inadequate). RESULTS: Seven hundred four patients were included in the efficacy analysis. The overall colon-cleansing response rates were comparable among treatment arms (94.5%, 97.0%, and 95.3% for NaP, RF-NaP 40, and RF-NaP 32 tablets, respectively). Ascending colon-cleansing response rates for RF-NaP 40 (95.7%) and 32 tablets (93.6%) were significantly better than for NaP tablets (88.5%, p < 0.03 for both). Patients treated with RF-NaP 32 tablets experienced less pronounced changes in electrolyte levels and fewer adverse events (138/239, 58%) compared with patients receiving NaP (161/238, 68%, p= 0.07) and RF-NaP 40 tablets (156/236, 66%, p= 0.03). The most common adverse events reported were abdominal distention, nausea, abdominal pain, and vomiting. CONCLUSIONS: Based on the safety, efficacy, and patient preferences, the 32-tablet RF-NaP regimen was superior to the 40-tablet RF-NaP and NaP regimen for colon cleansing prior to colonoscopy
PMID: 17029618
ISSN: 0002-9270
CID: 114400
Widespread occlusive vascular disease in a Crohn's disease patient with profound thrombocytosis [Letter]
Jay Wiesen, Ari; Kurtz, Leon E; Katz, Seymour
PMID: 17016147
ISSN: 0192-0790
CID: 114401
A case of recurrent epiploic appendagitis [Meeting Abstract]
Mian, Naima; Bernstein, David; Bonapace, Eugene; Katz, Seymour
ISI:000240656101073
ISSN: 0002-9270
CID: 3387132
Small bowel pseudopolyps: A unique finding on capsule endoscopy in a patient with Crohn's disease [Meeting Abstract]
Mian, Naima; Bernstein, David; Bonapace, Eugene; Katz, Seymour
ISI:000240656101072
ISSN: 0002-9270
CID: 3387142
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease
Burakoff, Robert; Barish, Charles F; Riff, Dennis; Pruitt, Ronald; Chey, William Y; Farraye, Francis A; Shafran, Ira; Katz, Seymour; Krone, Charles L; Vander Vliet, Martha; Stevens, Christopher; Sherman, Matthew L; Jacobson, Eric; Bleday, Ronald
BACKGROUND: Intestinal inflammation associated with Crohn's disease is characterized by a type 1 helper T cell response and elevated levels of interleukin (IL)-12. We report our clinical experience with a novel oral IL-12/IL-23 inhibitor (STA 5326) for the treatment of active Crohn's disease. MATERIALS AND METHODS: We conducted an open-label, dose-escalating trial of the orally delivered small molecule immunomodulator STA 5326 in 73 patients with active Crohn's disease (Crohn's disease activity index [CDAI] 220-450, inclusive). Five cohorts of patients were treated for up to 4 weeks with 14 mg twice a day (bid), 35 mg daily (qd), 28 mg bid, 35 mg bid, or 70 mg qd. The endpoints of the study included safety and improvement in clinical activity measured by the CDAI and the Crohn's disease endoscopic index of severity. RESULTS: STA 5326 was well tolerated. Reported adverse events were similar across dose cohorts. The most common (>15%) drug-related adverse events observed were dizziness, nausea, headache, and fatigue. Clinical activity at day 28/29 was observed at qd doses of 28 mg and above for the clinical endpoints of response and remission: 70 points or greater decrease in CDAI (range 42%-82% of patients); 100 points or greater decrease in CDAI (range 38%-64% of patients), and CDAI <150 (range 15%-36%). CONCLUSIONS: Oral qd dosing of STA 5326 for 4 weeks was well tolerated in doses up to 70 mg qd in patients with active moderate to severe Crohn's disease. Clinical activity was observed at qd doses of 28 mg and above
PMID: 16804392
ISSN: 1078-0998
CID: 114403